Nevertheless, based on the current data, it is questionable if BRD4 degradation is a viable therapeutic approach for targeted therapy rather than a cytotoxic treatment with a therapeutic window in aggressive cancers, similar to chemotherapy. Here, BRD4 is linked to cancer.